Active Ingredient History
CD137, a member of the tumor necrosis factor (TNF) receptor family, is a type 1 transmembrane protein, expressed on surfaces of leukocytes and non-immune cells. Its alternative names are tumor necrosis factor receptor superfamily member 9 (TNFRSF9), 4-1BB, and induced by lymphocyte activation (ILA). It is of interest to immunologists as a co-stimulatory immune checkpoint molecule, and as a potential target in cancer immunotherapy. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Biomarkers (Phase 1)
Breast Neoplasms (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Renal Cell (Phase 1)
Carcinoma, Transitional Cell (Phase 3)
Colorectal Neoplasms (Phase 1)
Lymphoma (Phase 3)
Lymphoma, Follicular (Phase 1)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Mantle-Cell (Phase 1)
Lymphoma, Non-Hodgkin (Phase 1)
Melanoma (Phase 1)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 3)
Oropharyngeal Neoplasms (Phase 2)
Ovarian Neoplasms (Phase 3)
Prostatic Neoplasms (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue